Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 6Recurrence 2Lymphoma, Non-Hodgkin 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma, B-Cell 2Waldenstrom Macroglobulinemia 1Optic Neuritis 1Neuromyelitis Optica 1Myelitis, Transverse 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma 1

Interventions

ublituximab 1ravulizumab 1eculizumab 1Sugars 1Rituximab 1OM 89 1Mitoxantrone 1LFB-R603 1Interferon beta-1a 14-Aminopyridine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Myelitis, Transverse × ublituximab × Clear all
NCT02276963 2019-06-06

Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses

Johns Hopkins University

Phase 1 Completed
6 enrolled 9 charts

Myelitis, Transverse, Neuromyelitis Optica, Optic Neuritis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡